Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
10/12/21	TearLab Corporation Announces Board Appointments	CI

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
10/12/21	TearLab Corporation Announces Board Appointments	CI
10/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
10/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
29/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/07/20	TearLab Corporation to Seek Acquisitions	CI
27/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/06/20	TearLab: 1Q Earnings Snapshot	AQ
27/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

TearLab Corp Stock Nasdaq

Stocks

US8781931014

Medical Equipment, Supplies & Distribution

Latest news: TearLab Corp

Press Releases: TearLab Corp

Managers and Directors: TearLab Corp

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ESSILORLUXOTTICA	-1.62%	-2.91%	-45.50%	-17.15%	78.34B
ALCON INC.	+0.53%	-0.93%	-10.84%	-25.37%	32.51B
LENSKART SOLUTIONS LIMITED	+0.54%	-0.38%	-	-	12.37B
THE COOPER COMPANIES, INC.	-1.06%	-20.62%	-17.94%	-37.22%	10.31B
SHANGHAI CONANT OPTICAL CO., LTD.	-1.02%	-4.76%	-5.65%	+563.09%	2.54B
AUTEK CHINA INC.	-1.20%	-9.84%	-45.09%	-61.61%	1.34B
SPYGLASS PHARMA, INC.	-3.16%	-4.20%	-	-	959M
PEGAVISION CORPORATION	+2.23%	+2.77%	+25.81%	+11.43%	921M
MINGYUE OPTICAL LENS CO.,LTD.	-0.81%	-5.16%	-39.92%	-24.99%	848M
Average	-0.64%	-4.28%	-19.87%	+58.31%	15.57B
Weighted average by Cap.	-0.88%	-2.96%	-33.01%	-9.57%

End-of-day quote Nasdaq
- ^USD	-